A new category forecast from IndexBox projects the global glutathione market growing at a 7.2% compound annual rate from 2026 to 2035, reaching a market index of roughly 200 by 2035 against a 2025 baseline of 100. IndexBox notes that indexed curves are used here because full absolute volumes are not publicly disclosed, which is worth holding onto before anyone quotes a dollar figure that does not exist.

Glutathione is a tripeptide antioxidant sold in capsules, tablets, powders and liquids, and the report describes it moving from a niche ingredient to a mainstream consumer health and beauty proposition. The commercial pitch sits on three claimed need states: skin brightening, detoxification and cellular protection.

Where the growth actually sits

Oral supplements are the largest and most dynamic end use in the report, with demand splitting into a value tier that wins volume in mass and online channels and a premium tier built on absorption claims such as liposomal and sublingual formats. IndexBox expects the premium brands that invest in claims architecture, patented forms and direct-to-consumer channels to capture disproportionate value, while the value segment grows volume under margin pressure.

Asia-Pacific remains the largest and fastest-growing region, supported by China, Japan and South Korea, where skin brightening is described as a well-established need state. North America and Europe follow, with what the report calls premiumization and clinical backing driving value growth.

The claims rules nobody has settled

The forecast's own caveat is regulatory. IndexBox lists the patchwork of structure and function claim rules as a watchpoint, says its baseline assumes only gradual regulatory clarity, and flags that regulatory clarity on claims will be critical for premium brand success.

That is the quiet admission inside a bullish number. A category projected to double its index in a decade is doing so partly on marketing language that regulators in several markets have not yet ruled on, and the report does not cite trial outcomes for any of the brightening or anti-aging claims it describes.

Bottom line

IndexBox is forecasting demand, not efficacy, and the two are easy to blur when the growth story is this clean. What stays unsettled is whether the claims driving the premium tier survive contact with the claim rules the report itself keeps naming.